Indication intelligence, analysis and sector perception

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Company Website

 

Verastem, Inc. | (VSTM)

5.31  $-0.28 (-28.00%) Jul 27, 5:53pm

August 5, 2015
RegMed’s close: pricing matters, technicals don't lie, the test of longer-term resistance is a red flag and any break below support levels make me nervous

August 2, 2015
RegMed weekend wrap-up: It’s a set-up for next week!

July 26, 2015
RegMed weekend wrap-up: why should we care what happened last week? It’s a set-up for next week!

July 22, 2015
RegMed’s close: drifting higher but, still whacked around

July 21, 2015
RegMed’s close: why whining before its time or is it?

July 21, 2015
RegMed’s mid-day: where are the canaries?

July 18, 2015
RegMed weekend wrap-up: a ladder is needed to climb up and down the tape

July 12, 2015
RegMed, what’s a weekend without a wrap-up; the sector ekes out weekly gains but what can be promised next week -the volume is falling like humpty-dumpty! Cracked but, not broken!

July 10, 2015
RegMed, so what can you promise investors – next week?

July 10, 2015
Higher open expected; RegMed, post rebound, who stays in the buy zone?

35 companies, 1 interpreter!

Insight, foresight and recommendation

Roll Call

Verastem (VSTM) --  Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...

hold

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

  Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.

           

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.